Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Biophytis S.A.

Healthcare US BPTSY

0.25USD
0.00(0%)

Last update at 2026-06-15T13:30:00Z

Day Range

0.250.25
LowHigh

52 Week Range

0.0013.36
LowHigh

Fundamentals

  • Previous Close 0.25
  • Market Cap4.58M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.86500M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-3.99

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -10.38500M -18.58700M -24.21600M -31.24700M -17.05400M
Minority interest 0.00000M 0.00000M 0.00000M 0.00100M 0.00000M
Net income -10.37900M -17.02600M -24.21600M -31.16300M -25.51700M
Selling general administrative 5.12M 5.49M 7.24M 7.15M 4.02M
Selling and marketing expenses - 0.42M 0.14M 0.93M 0.24M
Gross profit 0.00000M -0.80300M -0.48400M -0.31100M -0.28000M
Reconciled depreciation 0.30M 0.80M 0.48M 0.31M 0.28M
Ebit -8.50000M -14.33300M -23.52300M -26.81500M -13.94200M
Ebitda -8.25700M -13.80400M -23.03900M -26.50400M -13.66200M
Depreciation and amortization 0.24M 0.53M 0.48M 0.31M 0.28M
Non operating income net other - - - - -
Operating income -8.50000M -14.33300M -23.27200M -26.81500M -13.94200M
Other operating expenses 8.50M 14.33M 23.27M 26.82M 13.94M
Interest expense 1.53M 1.25M 1.60M 4.43M 4.37M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income - - - - -
Net interest income -1.32600M -1.40700M -2.46500M -2.52600M -1.50000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -1.56100M -1.52100M 2.28M 4.37M
Total revenue - 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 8.50M 14.33M 23.27M 26.82M 13.94M
Cost of revenue 0.00000M 0.80M 0.48M 0.31M 0.28M
Total other income expense net -1.88500M -4.25400M -0.94400M -4.34900M -11.57500M
Discontinued operations - - - - -
Net income from continuing ops -10.38400M -17.02600M -24.21600M -31.16400M -25.51700M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 6.90M 11.96M 21.99M 36.26M 27.21M
Intangible assets 2.61M 2.64M 2.65M 2.76M 2.67M
Earning assets - - - - -
Other current assets 3.85M 0.18M 2.16M 1.42M 5.66M
Total liab 16.60M 15.85M 23.90M 30.56M 20.38M
Total stockholder equity -9.66800M -3.85700M -1.87900M 5.74M 6.86M
Deferred long term liab - - - - -
Other current liab 6.52M 3.36M 2.10M 4.83M 6.23M
Common stock 0.73M 2.08M 47.66M 27.19M 20.15M
Capital stock 0.73M 2.08M 47.66M 27.19M 20.15M
Retained earnings -10.38400M -19.38300M -47.90500M -49.11100M -17.05400M
Other liab - - - - -
Good will - - - - -
Other assets - 0.02M 0.00000M 0.00000M -
Cash 0.08M 5.57M 11.05M 23.93M 5.85M
Cash and equivalents - - - - -
Total current liabilities 15.61M 12.37M 19.35M 23.14M 18.36M
Current deferred revenue - 0.18M 0.18M 0.17M 0.01M
Net debt 9.76M 0.51M 1.07M -8.55000M 3.25M
Short term debt 9.09M 3.52M 10.21M 8.37M 7.26M
Short long term debt 6.48M 3.47M 7.48M 8.15M 10.81M
Short long term debt total 9.84M 6.08M 12.13M 15.38M 9.10M
Other stockholder equity 15.28M 13.47M -1.60900M 27.83M 42.90M
Property plant equipment - - - - -
Total current assets 3.92M 8.85M 18.58M 31.69M 24.01M
Long term investments 0.00900M 0.03M 0.04M 0.07M 0.09M
Net tangible assets - - - - -
Short term investments 0.19M 0.37M 0.59M 1.23M 12.92M
Net receivables 0.08M 2.74M 5.20M 5.12M 5.21M
Long term debt - 2.42M 3.51M 4.39M 0.94M
Inventory - 0.00000M 1.57M -0.70900M 0.03M
Accounts payable 4.28M 5.35M 6.94M 7.61M 7.99M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -15.30200M -0.02500M -0.02500M -0.07300M -14.01300M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.14M 0.13M 0.12M 1.17M 0.32M
Deferred long term asset charges - - - - -
Non current assets total 2.98M 3.11M 3.41M 4.57M 3.20M
Capital lease obligations 0.14M 0.19M 0.47M 0.45M 0.00000M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - 0.37M -0.01700M 12.16M -12.71300M
Change to liabilities - - - - -
Total cashflows from investing activities 0.01000M - - - -
Net borrowings 4.00M - - - -
Total cash from financing activities 3.14M 7.03M 6.13M 29.71M 22.07M
Change to operating activities - - - - -
Net income -10.37900M -17.02600M -24.21600M -31.24700M -17.05400M
Change in cash -5.49200M -5.48500M -12.87300M 18.08M -0.49000M
Begin period cash flow 5.57M 11.05M 23.93M 5.85M 6.34M
End period cash flow 0.08M 5.57M 11.05M 23.93M 5.85M
Total cash from operating activities -8.64300M -12.87300M -18.98800M -23.79500M -9.86400M
Issuance of capital stock - 5.54M 0.00000M 16.58M 23.49M
Depreciation 1.06M 0.80M 0.48M 0.31M 0.28M
Other cashflows from investing activities 0.01000M - - - -
Dividends paid - 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory - - 0.40M 1.30M -2.65400M
Change to account receivables -1.36300M 1.67M -0.39800M -1.29700M 2.65M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.08500M 1.14M -1.28800M 12.84M -6.17100M
Change to netincome - - - - -
Capital expenditures 0.00000M 0.22M 0.14M 0.34M 0.21M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.36300M -0.02600M -1.33500M 1.32M 3.01M
Stock based compensation 0.74M 0.81M 5.57M 3.42M 0.79M
Other non cash items 1.30M 2.56M 0.51M 0.48M 4.52M
Free cash flow -8.64300M -13.09300M -19.12900M -24.13900M -10.07800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
BPTSY
Biophytis S.A.		 - -% 0.25 - - - 2.27 -0.4156
NVO
Novo Nordisk A/S		 -0.37 0.84% 43.55 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.0012 0.0027% 44.87 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 2.71 0.60% 453.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -0.25 0.04% 614.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.

Biophytis S.A.

14 avenue de l'Opéra, Paris, France, 75001

Key Executives

Name Title Year Born
Mr. Stanislas Veillet Ph.D. Chairman of the Board & CEO 1965
Mr. Waly Dioh Ph.D. Chief Clinical Operating Officer 1969
Dr. Pierre J. Dilda Ph.D. Chief Scientific Officer 1970
Dr. Rene Lafont Scientific Advisor & Member of Scientific Advisory Board 1946
Dr. Rob van Maanen FFPM, M.B.A., M.D. Chief Medical Officer 1971
Mr. Edouard Bieth Chief Business Officer 1980
Ms. Chiara Baccelli Chief Pharmaceutical Operations Officer & Quality Assurance Director NA
Ms. _ Teylan Financial Controller NA
Mr. Christophe Courtillat Chief Financial Officer NA
Mr. Waly Dioh Ph.D. Chief Operating Officer 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.